The Benefits of Starting a GLP-1 Earlier in Type 2 Diabetes

Why We Still Treat Type 2 Diabetes Like It’s 1995

Doctors have been treating diabetes the same way for decades. It usually goes something like this:

1. Start with diet, exercise, and metformin
2. Increase the metformin dose and/or add another medication like an SGLT2 inhibitor (Jardiance, Farxiga, Invokana), DPP-4 inhibitor (Januvia, Tradjenta), or sulfonylurea (Glucotrol, Glipizide)
3. Try a third medication
4. Add a GLP-1 or start insulin

This step-by-step process can take years, leaving blood sugar levels elevated and allowing complications to quietly develop. It’s a totally outdated strategy given the more effective options we have today. It’s the medical equivalent of renting DVDs from Blockbuster when you could be streaming them instead! 

Type 2 Diabetes Is Naturally Progressive 

One of the most important things to understand about type 2 diabetes is that it’s a progressive condition, which means it can worsen over time, even if you’re doing everything “right”.

When you’re newly diagnosed, your pancreas still produces insulin, but it either isn’t making enough or you aren’t responding to it well. This is called insulin resistance. In an effort to keep blood sugar in a healthy range, your pancreas tries to pump out more insulin.

Over time, that extra workload takes a toll. The insulin-producing beta cells begin to wear out, and insulin production declines. This makes blood sugar levels harder to control, and many people need more medications to keep their blood sugars in their target range.

Diabetes Complications Don’t Happen Overnight

Complications from diabetes don’t just suddenly appear out of nowhere. They’re due to chronically elevated blood sugar levels that damage blood vessels and nerves over the course of years. 

These complications are asymptomatic in the early stages (meaning you don’t have symptoms), so they’re harder to detect, and healthcare providers often miss them. But damage is occurring!

One of the most powerful ways to reduce the risk of complications is to keep blood sugar levels in a healthy range, which is why early, effective treatment is so important!

Starting a GLP-1 medication earlier in type 2 diabetes could help people reach healthy glucose levels sooner, and potentially protect against long-term complications.

What Are GLP-1 Medications?

GLP-1 medications mimic a natural hormone in the body called glucagon-like peptide-1. Your gut naturally releases GLP-1 after you eat. GLP-1 medications work by stimulating insulin secretion, reducing glucagon production (glucagon is a hormone that raises your blood sugar levels), and slowing stomach motility to help regulate blood sugar levels. GLP-1s also communicate with your brain to make you feel less hungry and help you to feel fuller faster.

Many GLP-1 options have dual indications, meaning the exact same medication is marketed under different brand names depending on whether it’s indicated for type 2 diabetes or weight management.

Here are a few of the most common GLP-1 options and GLP-1 indications: 

Tirzepatide (GLP-1/GIP dual agonist)

• Mounjaro (type 2 diabetes)
• Zepbound (weight loss)

Orforglipron

• Foundayo (weight loss)

Semaglutide

• Ozempic & Rybelsus (type 2 diabetes)
• Wegovy & Wegovy Pill (weight loss)

Dulaglutide

• Trulicity (type 2 diabetes)

Liraglutide

• Victoza (type 2 diabetes)
• Saxenda (weight loss)

The Benefits of GLP-1s

GLP-1 medications don’t just lower blood sugar and support weight loss; they work across the entire metabolic system.

They can help with:

• Heart Health: Lowering the risk of heart attack and stroke
• Kidney Protection: Slowing the progression of kidney disease
• Liver Health: Improving fatty liver disease
• Sleep Apnea: Improving sleep
• Blood Pressure: Supporting modest reductions in blood pressure
• Cholesterol: Lowering LDL and triglycerides
• Inflammation: Reducing systemic inflammation and osteoarthritis of the knee

So…Why Aren’t We Starting Them Sooner?

Current guidelines tend to prioritize starting a GLP-1 medication for people who already have cardiovascular or kidney disease, or for those where weight management is a concern.

But many people with type 2 diabetes have underlying risk factors, even if they haven’t had a heart attack or developed kidney disease. This is exactly what we’re trying to prevent!

That said, there are real-world barriers. Newer medications are more costly, and healthcare providers can take a long time to change their practice habits. Also, it can take years to complete studies that show additional benefits in other organs like the heart, kidneys, liver, etc. 

All of this slows down adoption. 

Shifting toward earlier use of GLP-1s starts with rethinking them as a proactive way to protect long-term health. Insurance providers need to get with the program too – getting people healthier earlier can save them money in the long run.

The Next Wave of GLP-1 Options: Bigger, Better, and More Powerful

A new generation of GLP-1 therapies is on the horizon, and they may be even more effective for both blood sugar and weight management.

Here’s what’s coming soon, and what’s in clinical trials:  

• Orforglipron (brand name Foundayo): A once-daily oral GLP-1 was just approved by the FDA for weight loss, and will hopefully be approved for type 2 diabetes soon. 
• CagriSema: A once-weekly injection that combines semaglutide with cagrilintide – another hormone that helps regulate appetite. It’s being studied for both diabetes and weight management, with an FDA decision expected in late 2026.
• Retatrutide: A “triple-agonist” (GLP-1/GIP/glucagon) that targets multiple metabolic pathways and has shown impressive weight loss results in studies.